Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.
There is no fundamental difference between ESGRO and recombinant mouse leukaemia inhibitor factor (mLIF) protein. Both can be used for the successful maintenance of mouse embryonic stem cell (ESC) pluripotency. 10E7 units of ESGRO is equivalent to 100 µg of pure protein. Thank you to Susanne van den Brink (postdoc in Anna Bigas lab, IMIM, Barcelona) and David Turner (University of Liverpool) for sharing their resuspension protocol to prepare ESLIF media.
June update with featured publication from Austin Smith lab, Kinoshita et al - capture of mouse and human stem cells with features of formative pluripotency; introduction to our "class of 2021" new products we've made this year; explaining pioneering proteins that bring innovative growth factors to stem cell researchers and free reconstitution solution to make lab life easy
We are proud to launch our Pioneering Protein range! A range of modified proteins have been carefully developed by world leading academic laboratories, licenced through Cambridge Enterprise, and then manufactured to our high purity and bioactivity standards, bringing together academic innovation with high level manufacturing purity. Folloistatin-resistant activin A (FRACTA) has been developed by our [...]
At Qkine we are so proud of all the wonderful women we work with! This #InternationalWomensDay we want to celebrate our amazing network and empower #WomenInSTEM to learn from and help each other #empoweringwomen #womenpower
The #21toWatch campaign showcases 7 people, 7 companies and 7 inventions at the forefront of innovation in Cambridge and the East of England. The results were announced on the 4th March and we are delighted that our CEO, Catherine Elton, was named one of the 7 “people” to watch.
Qkine, Manchester BIOGEL and Cellesce have been awarded Innovate UK Sustainable Innovation Funding to develop fully synthetic, chemically-defined three-dimensional (3D) scaffolds to enable manufacture scale up and improve reproducibility of patient-derived organoids.
Qkine is delighted to have been shortlisted in the prestigious Cambridge Independent 2020 Science and Technology Awards. Sponsored by Kao Data, the Startup of the Year shortlist recognises "early-stage companies that show entrepreneurial drive to solve a problem, or improve on what is already out there". Qkine would like to extend its congratulations [...]
We recently held a webinar with CytoSMART and organoid pioneers from Cold Spring Harbor Laboratory, Stemnovate and the Hubrecht Organoid Technology titled: what's needed to realize the potential of organoids? Following presentations from our speakers, we held an insightful Q&A session to address key challenges and questions from the audience. In this blog post, [...]
From standardization of imaging techniques, to more reproducible and cost-effective organoid culture media Organoids have the potential to revolutionize current drug discovery approaches, enhance the physiological relevance of in vitro disease models, and deliver on the promise of precision medicine. But, as with any new technology, there are a number of hurdles to overcome as [...]
